Similarly, a recent study evaluating the D-amino acid oxidase (DAAO) inhibitor luvadaxistat demonstrated a significant improvement in MMN amplitude at a 50-mg dose in patients with schizophrenia, consistent with enhanced NMDAR function. The gene discussed is DAO; the disease is schizophrenia.